Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Common Equity (2022 - 2025)

Entrada Therapeutics has reported Common Equity over the past 4 years, most recently at $306.1 million for Q4 2025.

  • Quarterly results put Common Equity at $306.1 million for Q4 2025, down 28.59% from a year ago — trailing twelve months through Dec 2025 was $306.1 million (down 28.59% YoY), and the annual figure for FY2025 was $306.1 million, down 28.59%.
  • Common Equity for Q4 2025 was $306.1 million at Entrada Therapeutics, down from $340.7 million in the prior quarter.
  • Over the last five years, Common Equity for TRDA hit a ceiling of $429.9 million in Q2 2024 and a floor of $206.9 million in Q2 2023.
  • Median Common Equity over the past 4 years was $273.4 million (2022), compared with a mean of $306.2 million.
  • Biggest five-year swings in Common Equity: skyrocketed 107.79% in 2024 and later dropped 28.59% in 2025.
  • Entrada Therapeutics' Common Equity stood at $212.6 million in 2022, then rose by 14.02% to $242.4 million in 2023, then surged by 76.88% to $428.7 million in 2024, then fell by 28.59% to $306.1 million in 2025.
  • The last three reported values for Common Equity were $306.1 million (Q4 2025), $340.7 million (Q3 2025), and $379.5 million (Q2 2025) per Business Quant data.